ESR1 and breast cancer: The patients with ER-low BC had a statistically significant worse DFS and overall survival (OS) compared with patients with ER-positive BC, whereas no differences were reported between the ER-low and ER-negative subgroups in a meta-analysis of retrospective studies that included patients with BC who received neoadjuvant chemotherapy (NAC) [36].